Cenduit’s launches upgraded Patient Reminders tool
Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, has launched its upgraded Patient Reminders tool. Designed to improve patient compliance and engagement without placing additional burdens on sites or sponsors, the expanded features include a two-way messaging dashboard and a mobile app available for iOS and Android devices.
As a large IRT specialist, Cenduit is leveraging the company’s expertise in clinical domain to improve sponsor-patient interactions throughout the duration of the trial. Using personalized messaging to remind patients of any scheduled appointments and necessary preparations for their clinical visit, Patient Reminders effectively improves patient compliance and retention in clinical trials, saving sponsors on costs resulting from patient dropout and noncompliance. The tool can be easily integrated with existing Interactive Response Technology (IRT) systems or as a standalone service, simplifying patient communications throughout the trial.
“Patient compliance is key to the success of any clinical trial. With our Patient Reminders tool, sponsors can have more control of their clinical trials and reduce patient dropout, which saves them time and money while increasing the quality of a trial’s endpoint data,” said Chris Dailey, global head of technology, Cenduit. “With new features, the upgraded tool gives sponsors a simple means to keep patients engaged in their trials by communicating in real time through the two-way messaging dashboard.”
The two-way messaging dashboard gives site users and sponsors a consolidated view of all interactions with patients. The dashboard allows for the monitoring of any reminders sent to patients, as well as their responses, to ensure the patients remain on track for any scheduled visits and medications.
Patients can also now send their responses to sponsors with an additional layer of security and privacy through the convenience of a mobile app, available for download on iOS and Android devices.